GNAO1 variants sort into two mechanisms, and Gβγ looks like a drug target
- Human genetic analysis and cellular assays sort GNAO1 variants into those predicted to sequester Gβγ and those with reduced Gαo expression, which increases free Gβγ signalling.
- Patient data link the Gβγ-sequestering class significantly to the hyperkinetic movement disorder NEDIM.
- In the GNAO1 R209H/+ mouse, caffeine and the Gβγ–effector modulator gallein both reduced hyperlocomotion; slice electrophysiology showed sex- and cell-type-specific hyperexcitability in dorsolateral striatal neurons.
💡 Points Based on the abstract
For a rare disease with no good drugs, getting patient genetics to predict mechanism, and then to predict which compound class to try, is exactly the order I like. The catch is gallein: it's a tool compound with a murky selectivity record, and a single hyperlocomotion readout in one knock-in line is thin. This is a preprint, so I'd treat Gβγ as worth a proper tool-compound validation, nothing more yet.